153 related articles for article (PubMed ID: 38258342)
1. Interleukin-4 induced 1-mediated resistance to an immune checkpoint inhibitor through suppression of CD8
Hirose S; Mashima T; Yuan X; Yamashita M; Kitano S; Torii S; Migita T; Seimiya H
Cancer Sci; 2024 Mar; 115(3):791-803. PubMed ID: 38258342
[TBL] [Abstract][Full Text] [Related]
2. Plasminogen activator inhibitor-1 promotes immune evasion in tumors by facilitating the expression of programmed cell death-ligand 1.
Ibrahim AA; Fujimura T; Uno T; Terada T; Hirano KI; Hosokawa H; Ohta A; Miyata T; Ando K; Yahata T
Front Immunol; 2024; 15():1365894. PubMed ID: 38779680
[TBL] [Abstract][Full Text] [Related]
3. IL4-induced gene 1 promotes tumor growth by shaping the immune microenvironment in melanoma.
Bod L; Lengagne R; Wrobel L; Ramspott JP; Kato M; Avril MF; Castellano F; Molinier-Frenkel V; Prévost-Blondel A
Oncoimmunology; 2017; 6(3):e1278331. PubMed ID: 28405502
[TBL] [Abstract][Full Text] [Related]
4. Disruption of tumour-associated macrophage trafficking by the osteopontin-induced colony-stimulating factor-1 signalling sensitises hepatocellular carcinoma to anti-PD-L1 blockade.
Zhu Y; Yang J; Xu D; Gao XM; Zhang Z; Hsu JL; Li CW; Lim SO; Sheng YY; Zhang Y; Li JH; Luo Q; Zheng Y; Zhao Y; Lu L; Jia HL; Hung MC; Dong QZ; Qin LX
Gut; 2019 Sep; 68(9):1653-1666. PubMed ID: 30902885
[TBL] [Abstract][Full Text] [Related]
5. The IL4I1 Enzyme: A New Player in the Immunosuppressive Tumor Microenvironment.
Molinier-Frenkel V; Prévost-Blondel A; Castellano F
Cells; 2019 Jul; 8(7):. PubMed ID: 31330829
[TBL] [Abstract][Full Text] [Related]
6. IL4I1 in M2-like macrophage promotes glioma progression and is a promising target for immunotherapy.
Ye F; Wang L; Li Y; Dong C; Zhou L; Xu J
Front Immunol; 2023; 14():1338244. PubMed ID: 38250074
[TBL] [Abstract][Full Text] [Related]
7. High baseline tumor burden-associated macrophages promote an immunosuppressive microenvironment and reduce the efficacy of immune checkpoint inhibitors through the IGFBP2-STAT3-PD-L1 pathway.
Wen Z; Sun H; Zhang Z; Zheng Y; Zheng S; Bin J; Liao Y; Shi M; Zhou R; Liao W
Cancer Commun (Lond); 2023 May; 43(5):562-581. PubMed ID: 37031362
[TBL] [Abstract][Full Text] [Related]
8. Functionalized biomimetic nanoparticles combining programmed death-1/programmed death-ligand 1 blockade with photothermal ablation for enhanced colorectal cancer immunotherapy.
Xiao Y; Zhu T; Zeng Q; Tan Q; Jiang G; Huang X
Acta Biomater; 2023 Feb; 157():451-466. PubMed ID: 36442821
[TBL] [Abstract][Full Text] [Related]
9. IL4I1: an inhibitor of the CD8⁺ antitumor T-cell response in vivo.
Lasoudris F; Cousin C; Prevost-Blondel A; Martin-Garcia N; Abd-Alsamad I; Ortonne N; Farcet JP; Castellano F; Molinier-Frenkel V
Eur J Immunol; 2011 Jun; 41(6):1629-38. PubMed ID: 21469114
[TBL] [Abstract][Full Text] [Related]
10. Shenqi Fuzheng injection modulates tumor fatty acid metabolism to downregulate MDSCs infiltration, enhancing PD-L1 antibody inhibition of intracranial growth in Melanoma.
Ma Y; Qi Y; Zhou Z; Yan Y; Chang J; Zhu X; Han J; Wu H; Tao Y; Fan F
Phytomedicine; 2024 Jan; 122():155171. PubMed ID: 37925891
[TBL] [Abstract][Full Text] [Related]
11. Diurnal Expression of PD-1 on Tumor-Associated Macrophages Underlies the Dosing Time-Dependent Antitumor Effects of the PD-1/PD-L1 Inhibitor BMS-1 in B16/BL6 Melanoma-Bearing Mice.
Tsuruta A; Shiiba Y; Matsunaga N; Fujimoto M; Yoshida Y; Koyanagi S; Ohdo S
Mol Cancer Res; 2022 Jun; 20(6):972-982. PubMed ID: 35190830
[TBL] [Abstract][Full Text] [Related]
12. What role for AHR activation in IL4I1-mediated immunosuppression ?
Castellano F; Prevost-Blondel A; Cohen JL; Molinier-Frenkel V
Oncoimmunology; 2021 May; 10(1):1924500. PubMed ID: 34026337
[TBL] [Abstract][Full Text] [Related]
13. High expression of IL4I1 is correlated with poor prognosis and immune infiltration in thyroid cancer.
Zhu L; Wang J; Hu J
BMC Endocr Disord; 2023 Jul; 23(1):148. PubMed ID: 37434155
[TBL] [Abstract][Full Text] [Related]
14. IL4I1 enhances PD-L1 expression through JAK/STAT signaling pathway in lung adenocarcinoma.
Zhu J; Li Y; Lv X
Immunogenetics; 2023 Feb; 75(1):17-25. PubMed ID: 36056935
[TBL] [Abstract][Full Text] [Related]
15. Thymol targeting interleukin 4 induced 1 expression reshapes the immune microenvironment to sensitize the immunotherapy in lung adenocarcinoma.
Li T; Shi J; Wang L; Qin X; Zhou R; Dong M; Ren F; Li X; Zhang Z; Chen Y; Liu Y; Piao Y; Shi Y; Xu S; Chen J; Li J
MedComm (2020); 2023 Oct; 4(5):e355. PubMed ID: 37655051
[TBL] [Abstract][Full Text] [Related]
16. ILT4 inhibition prevents TAM- and dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR activation.
Chen X; Gao A; Zhang F; Yang Z; Wang S; Fang Y; Li J; Wang J; Shi W; Wang L; Zheng Y; Sun Y
Theranostics; 2021; 11(7):3392-3416. PubMed ID: 33537094
[No Abstract] [Full Text] [Related]
17. Combination of ultrasound-based mechanical disruption of tumor with immune checkpoint blockade modifies tumor microenvironment and augments systemic antitumor immunity.
Abe S; Nagata H; Crosby EJ; Inoue Y; Kaneko K; Liu CX; Yang X; Wang T; Acharya CR; Agarwal P; Snyder J; Gwin W; Morse MA; Zhong P; Lyerly HK; Osada T
J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 35039461
[TBL] [Abstract][Full Text] [Related]
18. B Cells Are Required to Generate Optimal Anti-Melanoma Immunity in Response to Checkpoint Blockade.
Singh S; Roszik J; Saini N; Singh VK; Bavisi K; Wang Z; Vien LT; Yang Z; Kundu S; Davis RE; Bover L; Diab A; Neelapu SS; Overwijk WW; Rai K; Singh M
Front Immunol; 2022; 13():794684. PubMed ID: 35720386
[TBL] [Abstract][Full Text] [Related]
19. B16 melanoma control by anti-PD-L1 requires CD8+ T cells and NK cells: application of anti-PD-L1 Abs and Trp2 peptide vaccines.
Ji S; Lee J; Lee ES; Kim DH; Sin JI
Hum Vaccin Immunother; 2021 Jul; 17(7):1910-1922. PubMed ID: 33522416
[TBL] [Abstract][Full Text] [Related]
20. In situ immunogenic clearance induced by a combination of photodynamic therapy and rho-kinase inhibition sensitizes immune checkpoint blockade response to elicit systemic antitumor immunity against intraocular melanoma and its metastasis.
Kim S; Kim SA; Nam GH; Hong Y; Kim GB; Choi Y; Lee S; Cho Y; Kwon M; Jeong C; Kim S; Kim IS
J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33479026
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
